Neurophet

Neurophet P/B

The P/B (Price-to-Book Ratio) of Neurophet (380550.KQ) as of Oct 19, 2026 is 16.90. In the previous year, P/B (Price-to-Book Ratio) was -6.42 — a change of -363.19% (higher).

P/B

16.90

YoY

-363.19%

Last updated:

P/B (Price-to-Book Ratio) of Neurophet is 2025 16.90 . P/B (Price-to-Book Ratio) of Neurophet was 2024 -6.42 . It decreases by -363.19% higher compared to the previous year.

The Neurophet P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
-7.53 KRW
Jan 1, 2023
-8.97 KRW
Jan 1, 2024
-6.42 KRW
Jan 1, 2025
16.90 KRW
The Neurophet P/B history
YEARP/BYoY
16.90-363.19%
-6.42-28.42%
-8.97+19.22%
-7.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc is a South Korean company operating in the Health Care sector, headquartered in Seoul. The company has 135 employees and is listed on the Korean stock exchange with the ticker 380550.KQ and ISIN KR7380550004. Neurophet Inc went public on July 25, 2025, marking its initial public offering. The company focuses on the research, development, and sales of brain imaging analysis software, including PET image quantitative analysis software called 'Neurophet SCALE PET' and neurodegenerative brain disease diagnosis support software named 'Neurophet AQUA'. Additionally, Neurophet Inc develops and sells therapeutic medical devices and provides medical artificial intelligence solutions. The company's website is https://www.neurophet.com/. Neurophet Inc operates within the Health Care Technology industry, specializing in software and AI-driven tools for medical imaging and diagnostics. The company's products are designed to support healthcare professionals in analyzing brain imaging data and diagnosing neurological conditions. As a technology-focused health care provider, Neurophet Inc aims to enhance diagnostic accuracy and efficiency through its software solutions. The company's operations are based in Seoul, South Korea, and it is engaged in both the development and commercialization of its medical technology products. Neurophet Inc's business model centers on creating innovative software tools that address specific challenges in neurology and brain imaging analysis. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

P/B (Price-to-Book Ratio) of Neurophet is 16.90 in 2025.

P/B (Price-to-Book Ratio) of Neurophet changed from -6.42 to 16.90, representing a -363.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Neurophet since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Neurophet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neurophet

All Key Metrics — Neurophet